Casma Therapeutics, Inc. Company Profile

15:44 EDT 21st July 2018 | BioPortfolio

News Articles [778 Associated News Articles listed on BioPortfolio]

Casma Therapeutics raises $58.5m in Series A funding

Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.

With $59M, Casma and Ex-Constellation CEO Take Aim at Cellular Trash

Scientists have known for decades that cells can recycle their own trash, but they’ve only recently started to figure out how. Casma Therapeutics is trying to prove that those insights could be usef...

Casma Therapeutics Launches with $58.5 Million

Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.

Casma launched with $58.5mm Series A

Casma Therapeutics Inc. launched and concurrently raised $58.5mm in a Series A financing from Third Rock Ventures.

Rock the Casma

Third Rock launches Casma with $58.5 million A round to induce autophagy across a range of diseases.

STAT Plus: Is it time to target autophagy to treat disease? 

“The body’s natural ability to perform autophagy declines with aging, which likely contributes to the aging process itself,” said Dr. Beth Levine, of UT Southwestern and Casma Therapeutics.

Casma brings in $58.5M from Third Rock

Third Rock funnels $58.5M into autophagy newco Casma

PubMed Articles [447 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 2 of JOPT Special Issue.

Clinical Trials [146 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1244 Associated Companies listed on BioPortfolio]

Casma Therapeutics, Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Casma Therapeutics, Inc." on BioPortfolio

We have published hundreds of Casma Therapeutics, Inc. news stories on BioPortfolio along with dozens of Casma Therapeutics, Inc. Clinical Trials and PubMed Articles about Casma Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Casma Therapeutics, Inc. Companies in our database. You can also find out about relevant Casma Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record